ArticleAmerican journal of obstetrics and gynecology2016
Injectable silk-based biomaterials for cervical tissue augmentation: an in vitro study.
Article in American journal of obstetrics and gynecology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Recent Trends in Tissue Engineering Strategies for Uterine Endometrial Regeneration: a Systematic Review.Reproductive sciences (Thousand Oaks, Calif.) · 2026Pooled it
- Silk Fibroin Particle-Laden Sponges as a Multiphase Controlled Release Platform.Regenerative engineering and translational medicine · 2025Article
- Assessment of current biomarkers and interventions to identify and treat women at risk of preterm birth.Frontiers in medicine · 2024Review
- Tissue Engineering for Cervical Function in Pregnancy.Current opinion in biomedical engineering · 2022Article
- Sunitinib-Loaded Chondroitin Sulfate Hydrogels as a Novel Drug-Delivery Mechanism for the Treatment of Pancreatic Neuroendocrine Tumors.Annals of surgical oncology · 2021Article
- Next generation strategies for preventing preterm birth.Advanced drug delivery reviews · 2021Review
- Assessing the compatibility of primary human hepatocyte culture within porous silk sponges.RSC advances · 2020Article
- Cervical Augmentation with an Injectable Silk-Based Gel: Biocompatibility in a Rat Model of Pregnancy.Reproductive sciences (Thousand Oaks, Calif.) · 2020Article
- Injectable Silk-Based Hydrogel as an Alternative to Cervical Cerclage: A Rabbit Study.Tissue engineering. Part A · 2020Article
- Characterization of silk-hyaluronic acid composite hydrogels towards vitreous humor substitutes.Biomaterials · 2020Article
- Ex vivo pregnant-like tissue model to assess injectable hydrogel for preterm birth prevention.Journal of biomedical materials research. Part B, Applied biomaterials · 2020Article
- Bioactive Silk Hydrogels with Tunable Mechanical Properties.Journal of materials chemistry. B · 2018Article
- Prevention of preterm birth: Novel interventions for the cervix.Seminars in perinatology · 2017Review
- Shape Memory Silk Protein Sponges for Minimally Invasive Tissue Regeneration.Advanced healthcare materials · 2017Article
- Elastic, silk-cardiac extracellular matrix hydrogels exhibit time-dependent stiffening that modulates cardiac fibroblast response.Journal of biomedical materials research. Part A · 2016Article
- Silk Fibroin Scaffolds for Urologic Tissue Engineering.Current urology reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCerclage therapy is an important treatment option for preterm birth prevention. Several patient populations benefit from cerclage therapy including patients with a classic history of cervical insufficiency; patients who present with advanced cervical dilation prior to viability; and patients with a history of preterm birth and cervical shortening. Although cerclage is an effective treatment option in some patients, it can be associated with limited efficacy and procedure complications. Development of an alternative to cerclage therapy would be an important clinical development. Here we report on an injectable, silk protein-based biomaterial for cervical tissue augmentation. The rationale for the development of an injectable biomaterial is to restore the native properties of cervical tissue. While cerclage provides support to the tissue, it does not address excessive tissue softening, which is a central feature of the pathogenesis of cervical insufficiency. Silk protein-based hydrogels, which are biocompatible and naturally degrade in vivo, are suggested as a platform for restoring the native properties of cervical tissue and improving cervical function.
objectiveWe sought to study the properties of an injectable, silk-based biomaterial for potential use as an alternative treatment for cervical insufficiency. These biomaterials were evaluated for mechanical tunability, biocompatibility, facile injection, and in vitro degradation. STUDY
designSilk protein solutions were cross-linked by an enzyme catalyzed reaction to form elastic biomaterials. Biomaterials were formulated to match the native physical properties of cervical tissue during pregnancy. The cell compatibility of the materials was assessed in vitro using cervical fibroblasts, and biodegradation was evaluated using concentrated protease solution. Tissue augmentation or bulking was demonstrated using human cervical tissue from nonpregnant hysterectomy specimens. Mechanical compression tests measured the tissue stiffness as a function of the volume of injected biomaterial.
resultsSilk protein concentration, molecular weight, and concentration of cross-linking agent were varied to generate biomaterials that functioned from hard gels to viscous fluids. Biomaterials that matched the mechanical features of cervical tissues were chosen for further study. Cervical fibroblasts cultured on these biomaterials were proliferative and metabolically active over 6 days. Biomaterials were degraded in protease solution, with rate of mass loss dependent on silk protein molecular weight. Injection of cervical tissue samples with 100 μL of the biomaterial resulted in a significant volume increase (22.6% ± 8.8%, P < .001) with no significant change in tissue stiffness.
conclusionCytocompatible, enzyme cross-linked silk protein biomaterials show promise as a tissue bulking agent. The biomaterials were formulated to match the native mechanical properties of human cervical tissue. These biomaterials should be explored further as a possible alternative to cerclage for providing support to the cervix during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.